Kythera Biopharmaceuticals’ new drug application (NDA) for its ATX-101, a submental contouring injectable drug, has been accepted for filing by the US Food and Drug Administration (FDA).

According to Kythera Biopharmaceuticals, the ATX-101 NDA will be subject to a standard review and will have a prescription drug user fee act (PDUFA) action date of 13 May 2015. The company submitted the NDA in May 2014.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The FDA’s Division of Dermatology and Dental Products is also planning to hold an Advisory Committee meeting on the company’s ATX-101 application during the review.

"While the area under the chin is important to patients, there are no proven non-surgical options to effectively contour the area under the chin."

ATX-101 (deoxycholic acid) is currently in late-stage development for the reduction of submental fat, which commonly presents as a double chin. If approved, ATX-101 will be the first non-surgical treatment for the reduction of submental fat, the company claims.

Kythera Biopharmaceuticals president and CEO Keith Leonard said: "While the area under the chin is important to patients, there are no proven non-surgical options to effectively contour the area under the chin."

A formulation of a purified synthetic version of deoxycholic acid, ATX-101 destroys fat cells and contours the area under the chin.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

As present, the potential submental contouring injectable drug is in late-stage clinical trials. ATX-101 has been the focus of a global clinical development programme for the past seven years.

The global clinical development programme enrolled over 2,500 patients worldwide, of which more than 1,500 have been treated with ATX-101.